Dramatic improvement of DC-based immunotherapy against various malignancies

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Dendritic cells (DCs) play a crucial role in maintaining the immune system. Though DC-based cancer immunotherapy has been suggested as a potential treatment for various kinds of malignancies, clinical efficacies are still insufficient in many human trials. To identify the causes of the low efficacies, we paid attention to their numbers and how they are activated. We proved that DCs' antitumor effect depends on their number and the way they are activated. We here established a possible breakthrough, a simple cytokine-based culture method to realize a logscale order of functional murine/human DCs. Moreover, we demonstrated that DCs activated by replication-deficient recombinant Sendai virus (rSeV) were dramatically more effective than that seen in the use of current DC vaccine for immunotherapy against malignancies. Our study could overcome these problems and would improve treatment of malignancies.

Original languageEnglish
Pages (from-to)2233-2242
Number of pages10
JournalFrontiers in Bioscience
Volume16
Issue number6
DOIs
Publication statusPublished - Jun 1 2011

Fingerprint

Immunotherapy
Dendritic Cells
Neoplasms
Sendai virus
Immune system
Viruses
Immune System
Vaccines
Cytokines
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Immunology and Microbiology(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Dramatic improvement of DC-based immunotherapy against various malignancies. / Harada, Yui; Yonemitsu, Yoshikazu.

In: Frontiers in Bioscience, Vol. 16, No. 6, 01.06.2011, p. 2233-2242.

Research output: Contribution to journalArticle

@article{dd75197eaa124868aae206bf08ff1c0d,
title = "Dramatic improvement of DC-based immunotherapy against various malignancies",
abstract = "Dendritic cells (DCs) play a crucial role in maintaining the immune system. Though DC-based cancer immunotherapy has been suggested as a potential treatment for various kinds of malignancies, clinical efficacies are still insufficient in many human trials. To identify the causes of the low efficacies, we paid attention to their numbers and how they are activated. We proved that DCs' antitumor effect depends on their number and the way they are activated. We here established a possible breakthrough, a simple cytokine-based culture method to realize a logscale order of functional murine/human DCs. Moreover, we demonstrated that DCs activated by replication-deficient recombinant Sendai virus (rSeV) were dramatically more effective than that seen in the use of current DC vaccine for immunotherapy against malignancies. Our study could overcome these problems and would improve treatment of malignancies.",
author = "Yui Harada and Yoshikazu Yonemitsu",
year = "2011",
month = "6",
day = "1",
doi = "10.2741/3850",
language = "English",
volume = "16",
pages = "2233--2242",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "6",

}

TY - JOUR

T1 - Dramatic improvement of DC-based immunotherapy against various malignancies

AU - Harada, Yui

AU - Yonemitsu, Yoshikazu

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Dendritic cells (DCs) play a crucial role in maintaining the immune system. Though DC-based cancer immunotherapy has been suggested as a potential treatment for various kinds of malignancies, clinical efficacies are still insufficient in many human trials. To identify the causes of the low efficacies, we paid attention to their numbers and how they are activated. We proved that DCs' antitumor effect depends on their number and the way they are activated. We here established a possible breakthrough, a simple cytokine-based culture method to realize a logscale order of functional murine/human DCs. Moreover, we demonstrated that DCs activated by replication-deficient recombinant Sendai virus (rSeV) were dramatically more effective than that seen in the use of current DC vaccine for immunotherapy against malignancies. Our study could overcome these problems and would improve treatment of malignancies.

AB - Dendritic cells (DCs) play a crucial role in maintaining the immune system. Though DC-based cancer immunotherapy has been suggested as a potential treatment for various kinds of malignancies, clinical efficacies are still insufficient in many human trials. To identify the causes of the low efficacies, we paid attention to their numbers and how they are activated. We proved that DCs' antitumor effect depends on their number and the way they are activated. We here established a possible breakthrough, a simple cytokine-based culture method to realize a logscale order of functional murine/human DCs. Moreover, we demonstrated that DCs activated by replication-deficient recombinant Sendai virus (rSeV) were dramatically more effective than that seen in the use of current DC vaccine for immunotherapy against malignancies. Our study could overcome these problems and would improve treatment of malignancies.

UR - http://www.scopus.com/inward/record.url?scp=79959741428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959741428&partnerID=8YFLogxK

U2 - 10.2741/3850

DO - 10.2741/3850

M3 - Article

VL - 16

SP - 2233

EP - 2242

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 6

ER -